Innate Pharma SA
Dr Sally Bennett has a career spanning medicine, equity & capital markets and investment management. She brings over 20 years industry experience in senior roles across the financial sector within the life science and biopharmaceutical space.
She is currently a senior member of the private investment team (part-time) at HealthCor, a large healthcare focused US based investment firm where she co-leads the funds more recent move into private investing. Prior to HealthCor, she spent ten years as a senior financial analyst at ING Financial Markets and then at Piper Jaffray.
Dr Bennett serves as an Independent Non-Executive Director at BerGenBio, a publicly traded European biopharmaceutical company, where she Chairs the Audit Committee and is also an Advisory Board member of the P4 Precision Medicine Accelerator Programme in the UK.
This person is not in the org chart
This person is not in any offices
Innate Pharma SA
2 followers
Innate Pharma SA is a France-based biopharmaceutical Company that develops drugs for treatment of cancer and inflammatory diseases. The Company identifies and characterizes drug candidates, selects indications and manages the pre-clinical and clinical development of products. Innate Pharma primarily focuses on the development of new therapeutic solutions and monoclonal antibodies for the treatment of cancer, as well as for the treatment of infectious diseases and chronic inflammatory pathologies. The Company develops two categories of immunotherapies: immuno-modulators and cytotoxic antibodies. The Company works in collaboration with Bristol-Myers Squibb for Phase I cancer antibody program and with Novo Nordisk A/S for two antibody programs in inflammation treatment. The Company operates through anti-NKG2A antibody, an immune checkpoint inhibitor ready for Phase II development in oncology from Novo Nordisk.